Samsjuklighet vid bipolär sjukdom: Validering av risk/bio-markörer för bättre prevention och behandling - BIPCOM
| Reference number | |
| Coordinator | Örebro universitet - Örebro universitet Inst f medicinska vetenskaper |
| Funding from Vinnova | SEK 2 970 764 |
| Project duration | November 2022 - July 2026 |
| Status | Ongoing |
| Venture | European partnership for Personalised Medicine |
| Call | ERA PerMed Joint Transnational Call 2022: Personalised Prevention |
Purpose and goal
** Denna text är maskinöversatt ** Bipolar disorder (BD) is a common, and partially inherited, chronic and relapsing disorder that constitutes a critical public health problem. BD is linked to disability as well as extensive psychiatric and Medicinska Samsjuklighet (MS). However, there is extensive clinical heterogeneity, which means that there is an urgent need for personalized treatment and management. The overarching goal is to study medical comorbidities in people with bipolar disorder and to improve diagnostic and treatment outcomes with a precision medicine approach.
Expected effects and result
The successful implementation of the project will have a significant impact on the general health of people with BD, eventually leading to lower mortality rates and reduced incidence of severe disabilities, whilst providing reliable methods and tools for patients’ stratification and personalized treatments.
Planned approach and implementation
1. Identification of patients with BD and data collection (M3-18, TL P2-SE with P3-NO). 2. Development of Machine Learning (ML) models (M4-12, TL P2-SE with P3-NO). 3. Application of ML models (M13-30, TL P2-SE with P3-NO). BIPCOM will be implemented through continuous consultations with stakeholders, for ensuring results’ acceptability and transferability